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Introduction
The tumor suppressor protein p53 is a central component of a 
stress-activated signal transduction program that mediates a 
range of biological effects including DNA repair, apoptosis or 
senescence.1 The distinct array of gene products induced by the 
p53 transcriptional response mediates its tumor suppressor func-
tions.2 Stress-specific upstream kinase signaling events control 
the p53 activation pattern; DNA damage induces an ATM-
CHK2 signal; hypoxia induces a LKB-AMPK signal, oncogene 
activation induces the ARF-DAPK signaling cascades; and DNA 
virus infection can stimulate a CK1-dependent p53 activation 
suggesting together that different stresses recruit different sig-
naling modules to activate p53.3 Germline mutation or tumor 
derived mutation of these kinase networks can attenuate the p53 
response and contribute to enhanced cancer incidence.4
The multiple upstream signaling pathways that activate p53 
resulting in phosphorylation and proline isomerization con-
verge upon the key positive co-factor of p53, the transcriptional 
co-activator and acetyltransferase p300, which promotes p53 
acetylation.5 Conversely, in undamaged cells signaling networks 
maintain the function of the key negative regulator of p53, the 
ubiquitin ligase MDM2.6 Under these latter conditions, p53 pro-
tein is kept inactive by an undefined set of signaling pathways 
the regulation of p53 activity through the MDM2 negative feedback loop is driven in part by an extrinsic AtM-pulse 
that maintains p53 oscillations in response to DNA damage. We report here that the p53 pathway has evolved an 
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the DNA damage-induced p53 pulse. the p53 transcription program has evolved a negative feedback loop maintained 
by MDM2 that is counteracted by a positive feedback loop maintained by AtM-p21 the balance of which controls the 
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maintaining induction of its own inhibitor, MDM2.7 This forms 
the basis for the MDM2-dependent negative feedback loop that 
keeps p53 activity in check.8,9 More recent data has shown that 
WIP1 is a p53-inducible protein phosphatase that cooperates with 
MDM2 and forms a second key component of the p53-transcrip-
tion-driven negative feedback loop.10 Stresses that disengage the 
MDM2-negative feedback loop are ATM-dependent and results 
in signals that activate the p53 response.11 Recent studies have 
also highlighted the existence of an extrinsically activated pulse 
that results in ATM-activating or MDM2/WIP1-inhibitory 
waves of p53 protein synthesis and degradation that have formed 
the basis for deeper understanding of feedback control of the p53 
response.12 Together, these biochemical and genetic studies form 
the evidence for the core paradigm around which the specific 
activity of p53 is maintained by a balance between positive co-
factors like ATM and p53-inducible negative regulators MDM2 
and WIP1.
Transgenic studies in mice have been central in solidifying 
key paradigms in the p53 response and mice offer the opportu-
nity for quantitative genetics linked to cell signaling.13 Deletion 
of p53 results in viable animals with a strikingly enhanced cancer 
incidence,14 thus affirming that p53 is dispensable for develop-
ment but essential in pathways that mediate cancer suppression. 
Further, the introduction of an additional or activated p53 allele 
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that ATM-inhibition gives rise to a similar mislocalization of p53 
protein. p53 appears to have evolved a co-ordinated transcrip-
tion mechanism to control its own function via a positive branch 
maintained by p21 and a negative branch maintained by MDM2, 
the balance of which controls the specific activity of p53.
Results
Defects in p53 protein degradation and transcriptional activity 
in p21-null colorectal cancer cells. In order to begin to deter-
mine whether there is positive genetic interaction between the 
p53 pathway and the p21 gene, we first evaluated p53 protein 
steady-state levels and protein half-life in isogenic wild-type 
(hereafter referred to as wt) and p21-null colorectal cancer cells.25 
There are higher steady state-levels of p53 protein in p21-null 
cells (Fig. 1A, lane 2 vs. 1) highlighting some perturbation in 
p53 protein homeostasis in the absence of p21 protein (Fig. 1B, 
lane 2 vs. 1). A similar change in p53 protein levels were reported 
previously in HCT116 p21-null cells, which was attributed to the 
ability of p21 to function as a negative regulator of p53 protein 
stability.26 However, further analysis indicated that the elevated 
levels of wt-p53 protein in p21-null HCT116 cells is due to a 
striking increase in p53 protein half-life compared to p53 pro-
tein in wt-p21 containing cells (Fig. 1E, lane 1–5 vs. Fig. 1G, 
lane 1–5).
p53 protein can become more “stable” due to two distinct 
mechanisms; the first reflecting “activation” of the p53 transcrip-
tional response by a signal and the second reflecting “inactiva-
tion” of p53 d e to mutations that enhanced stability to do defects 
in MDM2-mediated degradation in p53-mutant cells. We per-
formed experiments to distinguish between these two possibili-
ties. The enhanced stability of p53 protein in p21-null cells was 
not attributed to a reduction in the specific activity of the protea-
some (Fig. 1I). Rather, this enhanced stabilization of p53 protein 
and/or defects in p53 protein degradation in the p21-null cells is 
a classic signature of inactive, mutant p53 in cancer cells result-
ing from defects in induction of the MDM2-negative feedback 
loop.27 Indeed, MDM2 protein induction is defective after ioniz-
ing radiation or doxorubicin treatment in p21-null HCT116 cells 
(Fig. 1J and N respectively, lanes 3 vs. 4), under conditions where 
p53 protein levels remain elevated (Fig. 1L/K and O respectively, 
lanes 3 and 4). As a control, a typical MDM2 protein induction 
after DNA-damage in wt-cells (Fig. 1J and N, lanes 2 vs. 1) can 
be compared to the standard p53 protein induction after DNA 
damage (Fig. 1L/K and O, lanes 1 vs. 2). Further, the classic 
ubiquitin-like modification on p53 protein induced by certain 
DNA damaging agents28 such as ionizing radiation and doxoru-
bicin (Fig. 1L/K and O respectively, lane 2 vs. 1) is also defective 
in the p21-null cells (Fig. 1L/K and O, lane 4 vs. 3), presum-
ably due to attenuation in MDM2 protein induction. This stabi-
lized p53 is transcriptionally inactive in p21-null cells as defined 
using a p53-responsive p21 luc-reporter based assays, relative to 
the p53-null HCT116 cell and the isogenic wt-HCT116 controls 
(Fig. 1Q). The data above indicate that p53 protein is highly 
stable, but transcriptionally attenuated, in p21-null colorectal 
cancer cells.
enhances tumor suppression,15,16 sometimes at a specific stage in 
the carcinogenic process.16 The p53 pathway can be subjected to 
quantitative analysis: deletion of one allele of p53 compromises 
damage-induced apoptosis to an intermediate degree compared 
to wt or null homozygous cells.17 The introduction of an addi-
tional p53 allele or a hypomorphic MDM2 allele into transgenic 
animals produces enhanced tumor suppression.18 The significant 
changes in p53 activity resulting from reduced or enhanced p53 
gene dosage suggest that cells have not evolved a classic genetic 
dosage compensation mechanism built into the p53-MDM2 neg-
ative feedback loop. Thus, a deeper understanding of quantitative 
control of the p53-MDM2 feedback loop will likely advance our 
understanding of how the tumor suppressor function of p53 is 
controlled.
Theoretical modeling has given novel insight into biological 
control of the p53 pathway. Single cell analyses have shown that 
the relative amounts of MDM2 and p53 oscillate with a fixed 
amplitude and time interval.19 The response of the p53-MDM2 
axis to increased stress by increasing the number of oscillations 
was interpreted to mean that the p53-MDM2 feedback is digital. 
However, although negative feedback loops are required for oscil-
lations to occur, a simple two component system incorporating 
MDM2 and p53 cannot oscillate.20 In other words, an unresolved 
qualitative problem with the p53:MDM2 negative feedback loop 
model is that there is no molecular mechanism to explain how 
p53 activity is switched on in the first place in undamaged cells 
to induce MDM2-mediated degradation of the p53 protein. One 
resolution could come from mathematical modeling which sug-
gested the possibility that there could be a positive input which 
has evolved an integration into the negative feedback loop.21 
Incorporating such a positive branch into the p53 negative feed-
back loop could resolve mathematical and biological discrepan-
cies with the oscillating nature of the negative feedback loop.
A logical hypothesis could be made that one possible can-
didate for a positive transcriptional branch to the p53-MDM2 
transcriptional feedback loop factor would be an intrinsic com-
ponent; a p53-inducible gene product that counteracts MDM2 
function. Such a candidate gene would form a positive feedback 
loop and it might also be a p53-inducible gene whose deletion 
in mice gives a similar phenotype to p53: enhanced cancer inci-
dence. The p53-inducible gene p21 fulfils partially this criteria 
based on three key genetic studies; p21-null animals have an 
increased spontaneous cancer susceptibility, although are cancer 
prone at an older age than p53-null mice,22 p21-null animals have 
an increase in metastatic tumors induced by irradiation,23 and 
the tumor spectrum in ATM-p21 double null animals are similar 
to that observed in p53-null animals.24 These latter data indicate 
that ATM and p21 are components of a positive genetic pathway 
that regulates cancer suppression in a manner similar to p53.
Given these tumor suppressor functions of p21 and the theo-
retical requirement of a positive component to the p53 feedback 
pathway, we evaluated the integrity of the p53 pathway in sets 
of cells with a reduced p21-gene dosage to determine whether 
p21 could be a component of a positive regulatory feedback. Our 
data demonstrate that loss of p21 compromises the p53 transcrip-
tional response in part due to p53 protein mislocalization and 
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Figure 1. the p53 protein pathway is aberrant in p21-null cells. (A–D) Analysis of p53 protein steady-state levels in HCt116 wt and p21-/- cells. HCt116 
Wt and p21-/- cells were lysed in urea lysis buffer, whole cell lysates were resolved by SDS-pAGe, and the indicated proteins were detected by immu-
noblotting. (D) An additional loading control depicts Coommassie Blue dye staining of total protein. (e–H) High basal level of p53 in the p21-/- cells is 
due to increased half-life of p53. Lysates were prepared from HCt116 Wt and p21-/- cells at 0–4 hr after addition of 30 μg/ml cyclohexamide (CHX) and 
p53 was detected by immunoblotting (e and G). Ink stain was used as a loading control (F and H). (I) proteasome activity is unaffected in p21-/- cells. the 
20s proteasome activity of HCt116 Wt and p21-/- cells was determined by monitoring the release of a fluorophore AMC (7-amino-4-methylcoumarin) 
from a proteasome specific peptide, using a 20s proteasome Assay Kit (Calbiochem). (J–p) MDM2 induction and damage induced Ubiquitination-like 
modifications on p53 is compromised in p21-/- cells. the indicated wt or p21-/- cell panels were treated with ionizing radiation (J–M) or doxorubicin 
(N–p) and the levels of MDM2 protein were analyzed by immunoblotting (J and N) and the levels of p53 protein (L and N) and ubiquitin-like adducts 
(K) were analyzed by Immunoblotting. Ink stain was used as a loading control (L and o). (Q) Specific reporter based transcriptional activity of p53 is 
reduced in p21-/- cells. the human p21 promoter fused to luciferase (1 μg) was introduced into HCt116 Wt, p21-/- and p53-/- cells together with 1 μg 
pCMV-βgal reporter. Cells were harvested 24 hr after transfection and lysed with 5x Reporter Lysis Buffer (promega). Luciferase activity was detected 
by a luminometer. p53-dependent activity (relative light units) is expressed as a ratio of p21-Luciferase activity to the internal transfection control 
β-gal.
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[hereafter referred to as poly(I).poly(C)],30 also resulted in reduced 
p53 activation in p21-null cells. If so, it would indicate a common 
signaling defect in both ATM-DNA damage (as in Fig. 1) and 
TLR3 signaling pathways. The treatment of wt-cells with poly(I).
poly(C) results in the induction of p53 protein, IRF-1 protein sta-
bilization, and GADD34 induction (Fig. 2A–D, lanes 2–6 vs. 1). 
By contrast, there was no detectable induction of IRF-1 or 
GADD34 proteins by poly(I).poly(C) in the p21-null cells 
(Fig. 2C and D, lanes 8–12 vs. 7). This was corroborated using 
the p21luc reporter where poly(I).poly(C) was only able to trig-
ger p21luc reporter activity in the wt-p21 cells (Fig. 2F). As con-
trols, a time course revealed the classic X-ray induced stabilization 
of p53 protein, MDM2 induction, and BAX perturbation after 
p53 responsive TLR3 and ATM signaling is defective in 
p21-null cells. To further evaluate whether there is a more pro-
found defect in the stress-activated p53 transcriptional response 
in p21-null cells, selected endogenous p53-responsive protein and 
mRNA products were quantified after exposure of cells to two 
distinct physiologically relevant stresses resulting from anti-viral 
or DNA damage sensing pathways. p53 protein is known to be 
required for both DNA-damage and the DNA/RNA anti-viral 
response,29 although how cells activate p53 in response to dis-
tinct stresses is not fully defined. Nevertheless, as p21-null cells 
are defective in p53 transcriptional activation in response to DNA 
damaging agents (Fig. 1), we evaluated whether the treatment 
of cells with the TLR3 ligand Polyinosinic polycytidylic acid 
Figure 2. p53 pathway induction by poly(I).poly(C) or X-ray signaling is attenuated in p21-null cells. (A–e) the p53 tLR3 anti-viral response is sup-
pressed in p21-/- cells. HCt116 Wt and p21-/- cells were treated with the tLR3 ligand 50 μg/ml poly(I).poly(C) and harvested at the stated time points. 
Cells were lysed with urea lysis buffer. Whole cell lysates were resolved by SDS-pAGe and p53, p21, IRF-1 and GADD34 were detected by immunoblot-
ting. β-actin was used a loading control. (F) p53 transcriptional reporter activity in response to poly(I).poly(C) was compromised in p21-/- cells. HCt116 
Wt and p21-/- cells were transiently transfected with 1 μg p21-Luciferase and 1 μg pCMV-βgal reporter and treated with 50 μg/ml poly(I).poly(C) 24 hr 
after transfection. Cells were harvested at the time points indicated and lysed with 5x Reporter Lysis Buffer (promega). Luciferase activity was detected 
by a luminometer. p53-dependent activity (relative light units) is expressed as a ratio of p21-Luciferase activity to the internal transfection control 
β-gal. (G–K) the p53 AtM DNA damage response is suppressed in p21-/- cells. HCt116 Wt and p21-/- cells were treated with 7 Gy of ionizing radiation (IR) 
and harvested at the stated time points. Cells were lysed with urea lysis buffer and whole cell lysates were resolved by SDS-pAGe and immunoblotting 
to detect p53, MDM2, p21, BAX and β-actin. (L) p53 transcriptional reporter activity in response to IR was compromised in p21-/- cells. HCt116 Wt and 
p21-/- cells were transiently transfected with 1 μg p21-Luciferase and 1 μg pCMV-βgal reporter and treated with 7 Gy IR 24 hr post-transfection. Cells 
were harvested at the time points indicated and lysed with 5x Reporter Lysis Buffer (promega). Luciferase activity was detected by a luminometer. 
p53-dependent activity (relative light units) is expressed as a ratio of p21-luciferase activity to the internal transfection control β-gal.
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that the p21-null cells are more sensitive to oxaliplatin under 
conditions where p53-null cells are more resistant, relative to wt-
cells (Fig. 3I). Resistance of cells to certain damaging agents as a 
result of p53-deletion and conversely, the sensitivity as a result of 
p21-deletion has been observed previously in reference 33 and 34, 
indicating that the isogenic cell panels we used are representative. 
Thus, the apoptotic phenotypes of p21-null and p53-null cells do 
not co-segregate under these conditions, in contrast to the p53 
dependent transcriptional phenotypes described above.
Complementation of the p21 gene in p21-null cells restores 
the p53 TLR3 and DNA damage response. The HCT116 cell 
line is hyper-recombination proficient and it remained possible 
that the p53 transcriptional defects seen in p21-null cells was 
due to additional mutations accumulated in these cells over time 
since their construction.25 This might be less likely considering 
the survival and cell cycle parameters analyzed in Figure 3 that 
recapitulate classic cell responses in the absence of p21. However, 
we evaluated whether reduced p53 activity in p21-null cells was a 
single gene defect by analyzing p53 function after the generation 
of p21-null clones which re-express the human p21 gene driven 
from a constitutive CMV promoter. Such p21-complemented 
cells re-express basal levels of BAX and MDM2 protein relative 
to p21-null cells which do not express detectable BAX or MDM2 
irradiation in the wt-p21 cells (Fig. 2G–J, lanes 2–6 vs. 1). By con-
trast, MDM2 induction was not detected after irradiation nor was 
any BAX protein detected in the absence or presence of irradiation 
in the p21-null cells (Fig. 2H and J, lanes 8–12 vs. 7). This was 
corroborated using p21luc reporter assays where there were defects 
in the irradiation-induced activation of the p21 reporter (Fig. 2L).
As a control, we evaluated the integrity of the p21-null cells 
which have been previously shown to be sensitive to certain DNA 
damaging agents under conditions in which p53-null cells resist 
damage induced lethality.25,31 Exposure of cells to the topoi-
somerase I inhibitor SN3832 results in S-phase dependent DNA 
damage and a G
2
/M arrest in a panel of HCT116 cells (wt, bax-
null, p53-null and p21-null; Fig. 3A–D). These data indicate 
that the p21-null and wt cells exhibit an intact p53-independent 
checkpoint program in response to this insult. However, the 
exposure of wt or bax-null cells to oxaliplatin, which generates 
S-phase independent DNA damage, results in a G
1
 cell cycle 
block (Fig. 3E and F) that is defective in p21-null and in p53-
null cells (Fig. 3G and H). These data indicate that the p21-null 
and p53-null growth arrest phenotypes co-segregate and that the 
G
1
 arrest damage response, which is at least in part dependent 
on p53 dependent transcription is selectively reduced in these 
genetic backgrounds. Clonogenic survival assays demonstrate 
Figure 3. Cell cycle analysis of HCt116 wt and p21-null cells. the indicated HCt116 cell parts were treated as indicated (A–D) with SN38 and (e–H) with 
oxaliplatin. Cells were processed after (time) and processed for cell cycle analysis as reported previously in reference 32. (I) Clonogenic survival was 
also performed with the indicated cell parts as a function of oxaliplatin concentration.
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Distinct subcellular localization of p53 protein in p21- null 
cells. As p53 protein is transcriptionally attenuated in response to 
two distinct stresses in the p21-null cell (Fig. 2), there is presum-
ably a common mechanism that accounts for why different stress-
responsive systems cannot engage the p53 pathway in this genetic 
background. Five of the most common ways for p53 protein to be 
inactivated include defects in ATM-pathway activation,35 stimu-
lation of MDM2-mediated trans-suppression of p53 at chroma-
tin,36 increases in histone deacetylase functions,37 increases in p53 
nuclear export,38,39 and p53 protein unfolding and inactivation 
which can sensitize p53 to hyperubiquitination and degrada-
tion.40,41 All of these phenomena have been shown to occur in can-
cer cell lines and provide an explanation for how the p53 protein 
pathway can be inactivated post-translationally in cancer cells.
proteins (Fig. 4C and D, lane 13 vs. lane 7). In response to DNA 
damage, the p21-complemeted cells also responded by transient 
induction of MDM2 protein (Fig. 4D, lanes 13–18). These data 
indicate that the classic p53 signature, namely MDM2 and BAX 
protein expression, can be restored in p21-null cells by comple-
mentation of the p21 gene. A similar reconstitution in TLR3 
signaling was observed after complementing the p21 gene in 
p21-null cells. Relative to the control p21-null cells which fail 
to induce IRF1 or GADD34 after poly(I).poly(C) treatment 
(Fig. 4H and I, lanes 1–7), the p21 expressing p21-null cells 
exhibited poly(I).poly(C)-dependent induction of p53, IRF1 and 
GADD34 (Fig. 4G–I, lanes 8–14). These data indicate that the 
p53 transcription defect in p21-null cells is due predominately to 
a single gene defect.
Figure 4. Complementation of the p21 gene into p21-null cells restores the p53 transcriptional response. HCt116 Wt, p21-/-, p21-complemented p21-/- 
cells were treated with the (A–e) IR or (F–J) poly(I).poly(C) and harvested at the stated time points. Cells were lysed with urea lysis buffer. Whole cell 
lysates were resolved by SDS-pAGe and the indicated proteins were quantified by immunoblotting.
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whether p53 protein has reduced association with chromatin 
fractions,42 which might explain in part its lowered specific activ-
ity. On the other hand, if p53 protein was localized equivalently 
on chromatin fractions in wt and p21-null cells, there might 
be suppressing factors like MDM2 recruited to attenuate p53 
function at promoters.36 When nuclei are purified, chromatin is 
We first evaluated whether p53 protein is in a “mutant” and 
inactive conformation in p21 null cells, which might occur if 
there were general misfolding defects. However, using monoclo-
nal antibodies that can quantify the extent of folded or unfolded 
p53 protein, the p53 protein in wt and p21-null cells was in the 
wild-type conformation (data not shown). We next evaluated 
Figure 5. p53 protein is mislocalized in p21-/- cells. Loss of p21 is associated with mislocalization of p53 as defined using chemical sub-cellular frac-
tionation. (A and B) p21-/- cells have reduced p53 protein in the chromatin fractions. Nuclei were isolated from HCt116 Wt and p21-/- cells and were 
subsequently chemically fractionated into: e-total cellular extract; p-insoluble nuclear fraction; SN-soluble nuclear chromatin containing fractions 
as described previously in reference 42. p53 protein levels were detected by Immunoblotting. (C) Subcellular fractionation protocol. proteins from 
HCt116 Wt and p21-/- cells were extracted according to their subcellular localization: F1-Cytosol; F2-Membrane/organelle; F3-Nucleus; F4-Cytoskeleton 
(proteoextract® Subcellular proteome extraction Kit (S-peK), Calbiochem®). (D–M) Selectivity of p53 mislocalization in p21-/- cells. the indicated cell lines 
were subjected to subcellular fractionation and the proteins from each fraction were resolved by SDS-pAGe and analyzed by immunoblotting for: p53; 
p21; HSp70, pML; CHK2; CHK1; 14-3-3; and Cyclin e. (N–p) p53 protein subcellular localization after irradiation. the indicated cell lines were subjected to 
subcellular fractionation before or after irradiation and the proteins from each fraction were resolved by SDS-pAGe and analyzed by immunoblotting 
for: p53, CHK2 and total protein after staining with Coommassie Blue.
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for changes in localization equilibrium including CHK2, CHK1, 
14-3-3 and Cyclin E (Fig. 5I–M). As a control, DNA damage 
by irradiation of wt-cells increased the levels of p53 protein in 
the F3 nuclear fraction (Fig. 5N, lane 11 vs. 3), whereas irradia-
tion of p21-null cells did not result in p53 nuclear accumulation 
(Fig. 5N, lane 13 and 14 vs. 5 and 6). Confocal microscopy was 
also used to reveal a shift of human p53 protein from predomi-
nantly nuclear pools in wt cells (Fig. 6E) to enhanced cytosolic 
pools in p21-null cells (Fig. 6B).
Complementation of the p21 gene into p21-null cells can 
restore the p53 pathway (Fig. 4) and we evaluated whether 
this correlated with nuclear re-localization of the p53 protein. 
Relative to the control samples in which p53 protein from wt-
cells was distributed in the F3 nuclear fraction (Fig. 7A, lane 3) 
and p53 protein from p21-null cells was distributed in the 
cytosolic fractions (Fig. 7A, lane 5–7), the p21-null cells com-
plemented with the p21 gene restored the F3 nuclear localiza-
tion of p53 (Fig. 7A, lane 11). Further, p21 localized to the F1 
and F2 cytosolic fractions in the complemented p21-null cells 
(Fig. 7C, lanes 9 and 10) that is similar to p21 subcellular local-
ization in the wt-cells (Fig. 7C, lanes 1 and 2). The C-terminus 
of the p21 gene has the major binding site for PCNA, which 
comprises a major function of p21 (Fig. 7E).43 A form of p21 
with a deletion of the C-terminus (1-133) was able to stimulate 
extracted into the soluble nuclear fraction and remaining mate-
rial sediments with insoluble material. In wt cells, the major-
ity of p53 protein is present in the soluble chromatin fraction 
(Fig. 5A, lane 3) with little p53 present in the insoluble pellet 
(Fig. 5A, lane 2). However, in the p21-null cells, p53 protein is 
not chromatin associated but sediments in insoluble fractions 
(Fig. 5B, lane 2). These data indicate that in nuclear fractions 
from p21-null cells, the p53 is mislocalized away from soluble 
chromatin fractions and we therefore evaluated whether p53 
protein is generally mislocalized in p21-null cells using chemical 
fractionation methodologies that can extract proteins differen-
tially from distinct subcellular compartments (Fig. 5C).
Fractionation of cells into cytosolic, membrane, nuclear and 
cytoskeletal fractions demonstrated that p53 protein is predomi-
nantly nuclear in wt HCT116 colon cancer cells (Fig. 5D, lane 3), 
whereas p53 protein was largely cytosolic in the p21-null cells 
(Fig. 5D, lane 5 and 6). This change in localization is consistent 
with the distinct redistribution of p53 from the chromatin frac-
tions in wt-cells to the insoluble nuclear pellet in p21-null cells 
(in Fig. 5A and B). This effect was relatively specific for p53, 
since HSP70 and PML were not grossly mislocalized in p21-null 
cells (Fig. 5F and G). Total protein content in each sub-cellular 
fraction can be evaluated qualitatively, as shown in Figure 5H. 
For comparison, other checkpoint proteins were also examined 
Figure 6. enhanced cytoplasmic expression of p53 protein in p21-null cells defined using microscopy. the indicated cells [p21-null, (A–C); and wt-(D 
and e)] were fixed and processed for immunochemical evaluation of p53 protein localization with a to-pRo3 nuclear counter stain using a Leica tCS 
Sp5 confocal microscope.
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p53 responsive genes relative to controls 
(Fig. 8F and H). Irradiation can induce 
some of the p53-responsive genes in cells 
depleted of p21 protein (Fig. 8G), includ-
ing CDK4 and MDM2 (Fig. 8I and J), 
indicating that siRNA depletion of p21 is 
not able to fully inactivate the p53 path-
way. Subcellular fractionation studies 
also indicated that siRNA to p21 shifted 
the equilibrium of p53 from nuclear 
(Fig. 8K, lane 3) to the cytosolic fractions 
(Fig. 8K, lane 5). The elevated pool of 
nuclear p53 protein in cells depleted of p21 
protein (and the increased activity after 
DNA damage) using siRNA might reflect 
the relative inefficiency of siRNA to fully 
deplete p21 protein, as is done by genetic 
deletion in the HCT116 cells.
A more quantitative genetic screen is 
therefore required to establish whether 
p21 plays a positive role in regulating the 
p53 transcriptional response in normal 
untransformed cells. Murine B-cells have 
proven to be a genetically well-defined in 
vitro cell model with which to analyze the 
pro-apoptotic function of p53 in vitro, for 
example reduced p53-dependent func-
tion after mutation of the transactivation 
domain phospho-acceptor site at Ser-23.45 
There have been previous reports indicat-
ing that animals have enhanced cancer 
susceptibility in a p21-heterozygote or 
p21-null background,46 p21-null animals 
are tumor prone but tumors development 
is much more delayed than in p53-null 
animals,22 p21-deletion attenuates the tumor suppressor function 
of super-p53 mice,47 and p21 loss blocks senescence and stimu-
lates tumorigenesis in renal but not intestinal tissue.48 There is 
therefore precedence in p21-null murine cells for enhanced cancer 
phenotypes that could be consistent with reduced specific activity 
of p53. After purifying B-cells from: (1) wt p21 homozygous ani-
mals; (2) mice heterozygous for p21; and (3) animals null for the 
p21 locus, RNA was isolated to measure steady-state expression of 
known murine p53 responsive genes normalized to standardized 
control promoters. A quantitative reduction in p53-responsive 
gene levels were observed as a function of reduced p21 gene dos-
age (Fig. 9A–C and quantified in F and G). Some gene products 
like MDM2 are more sensitive to loss of one p21 allele (Fig. 9H), 
whilst other genes like BAX exhibit relatively higher activity 
in p21-heterozygotes and require both p21 alleles to be deleted 
before reduction in gene expression can be observed (Fig. 9J). 
The reductions in gene expression in the p21-null B cells can be 
attributed in part to the shift in p53 equilibrium from the nuclear 
F3 fraction to the cytosolic fractions (Fig. 9D, lanes 1 and 3 
vs. lanes 5 and 7). Together, these studies indicate that normal 
human fibroblasts or murine B-cells require p21 to maximize the 
the re-localization of p53 protein into the F3 nuclear fraction 
(Fig. 7D, lane 4 vs. 5 and 6) indicating that this p53 stimulatory 
function of p21 appears to be distinct from its PCNA binding 
functions. An uncoupling of p21 growth arrest functions from 
PCNA binding has been previously reported in reference 44.
Non-transformed cells require p21 to maintain maximal p53 
function and nuclear localization. The experiments described 
thus far have examined the contribution of p21 to p53 function 
using a well-established colorectal cancer cell line. It remains pos-
sible that this function of p21 is confined to tumor cell lines and 
to evaluate this we evaluated the role of p21 in the p53 pathway 
in normal human fibroblasts. The reduction in p21 protein using 
siRNA to p21 (Fig. 8A, lane 2 vs. 1) results in reduced levels of 
the p53-responsive gene product BAX (Fig. 8C, lanes 2 vs. 1). 
This is suggestive of reduced p53 function and is similar to the 
reduced basal BAX protein in p21-null HCT116 cells (Fig. 2). 
A p53 gene expression array was used to evaluate whether there 
were defects in the expression of common p53-responsive genes 
after p21 protein depletion using siRNA. Relative to the control 
panels that produce the highlighted levels of p53 responsive genes 
(Fig. 8E), reduction in p21 resulted in substantial reduction in 
Figure 7. Complementation of the p21 gene into p21-null cells restores the p53 nuclear localiza-
tion. (A–C) p53 localization in HCt116 cell parts. HCt116 Wt, p21-/-, p21-complemented p21-/- cells 
were subjected to subcellular fractionation and the proteins from each fraction were resolved 
by SDS-pAGe and analyzed by immunoblotting for: p53, CHK2 and p21. (D) p53 localization in 
HCt116 cell parts after p21 (1–133) complementation. p21-/- cells were transfected with full length 
p21 (lanes 1 and 2) or p21(1–133) (lanes 3 and 4) were subjected to subcellular fractionation and 
the proteins from each fraction were resolved by SDS-pAGe and analyzed by immunoblotting for 
p53. Controls fractionations included vector transfected p21-/- cells (lanes 5 and 6) and untrans-
fected wt-cells (lanes 7 and 8). (e) Diagram of the p21 linear binding motif structure including the 
cyc1 and cyc2 helices, the cdk binding site, and the C-terminal pCNA binding site which is deleted 
in the truncated p21 (1–133) isoform.
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Figure 8. the p53 transcriptional response is attenuated by depleting p21 using siRNA in normal human fibroblasts. (A–D) p21 depletion using siRNA. 
Fibroblasts were treated with p21-specific or control siRNA for 48 hours and lysates were immunoblotted as indicated for p21, p53, Bax and β-actin. 
(e–H) p21 depletion using siRNA in normal human fibroblasts shows defects in basal and x-irradiation induced p53-dependent gene expression. Fibro-
blasts treated with control siRNA or p21-specific siRNA were left unirradiated (e and F) or irradiated with 7 Gy after p21-siRNA treatment (G) and incu-
bated for 4 hr. DNA microarrays were used to profile the expression of genes related to p53-mediated signal transduction (oligoGeArray® System, Super-
Array) to indicate the extent of p53 activity. Housekeeping gene expression is indicated by red arrows. the part of genes analyzed in detail are indicated 
by the red boxes and representative changes in gene expression of selected p53 responsive genes using GeArray expression Analysis Suite software. (H) 
Graphical representation of NHF microarray results shows a general reduction of gene expression in the absence of p21. Gene expression is partially re-
covered in response to x-irradiation. Representative genes include CDK4 (I) and MDM2 (J). (K–M) p53 protein is mislocalized in normal human fibroblasts 
treated with siRNA specific for p21. Fibroblasts treated with control or p21-specific siRNA were extracted according to their subcellular localization: F1-
Cytosol; F2-Membrane/organelle; F3-Nucleus; F4-Cytoskeleton (proteoextract® Subcellular proteome extraction Kit (S-peK), Calbiochem®). proteins from 
each fraction were resolved by SDS-pAGe and analyzed by immunoblotting for: p53, p21 and total Coommassie blue stained protein.
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Figure 9. For figure legend, see page 943.
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of p53 protein from the nucleus to cytosolic fractions was also 
observed in normal human fibroblasts (Fig. 10L, lane 5 vs. 1), 
under conditions in which the DNA-PK inhibitor had no effect 
on p53 localization (Fig. 10L, lanes 9 and 11 vs. lanes 1 and 3). 
Finally, the redistribution of p53 protein from the nuclear to 
the cytosolic fraction after siRNA to p21 in normal human 
cells (Fig. 10H, lanes 5 and 6 vs. 1 and 2) was not rescued after 
depletion of MDM2 using siRNA (Fig. 10K, lanes 5 and 6 vs. 
Fig. 10I, lanes 5 and 6). These data indicate that the predomi-
nant mechanism of p21-maintenance of p53 protein localization 
is ATM-dependent and not MDM2-dependent.
p21 protein oscillates and maintains the ATM-p53 pulse 
after DNA damage. ATM is a component of an extrinsic DNA 
damage recognition pathway that maintains p53 protein activa-
tion pulses.12 Accordingly, given that p53 nuclear localization 
in undamaged cells depends on both p21 and ATM gene prod-
ucts (Fig. 10) we evaluated whether p21 protein is a component 
of a similarly cycling system. In growing HCT116 cells, p21 
protein exhibits an oscillating pattern (Fig. 11A and p21 part, 
lanes 2, 7, 12 and 18) giving a periodicity of approximately 
2.5–3 hours. This oscillation of p21 is generally uncoupled 
from basal MDM2 protein levels over the 10 hours time course 
(Fig. 11A and MDM2 part). In MCF7 cells which are classically 
used to study p53 activation and which were used to originally 
define the ATM pulse,12 undamaged cells also exhibit a cycling 
p21 protein expression pattern (Fig. 11D and E, lanes 1–9) with 
a periodicity of approximately 4 hours. Under these conditions, 
p53 and MDM2 proteins gradually accumulated as cells reached 
more confluent conditions (Fig. 11B/C and F/G, lanes 1–9), but 
neither p53 nor MDM2 exhibited the same degree of oscillation 
as p21 protein. After ionizing irradiation (2.5 Gy), the progres-
sively decaying pulse of p53 is induced (Fig. 11B and C, lanes 
13, 15 and 18), along with a consistently elevated p21 oscilla-
tion (Fig. 11D and E, lanes 15 and 18), and an MDM2 pulse 
(Fig. 11F and G, lanes 13, 15 and 18). The irradiation-induced 
p53, MDM2, and p21 pulse are largely co-incident after 2.5 Gy 
irradiation (lanes 13, 15 and 18). At higher doses of radiation 
(5 Gy), the p53 pulse is not evident (Fig. 11, lanes 19–26); pre-
sumably the p53 pulse is sensitive to the extent of damage and 
higher levels of irradiation might reflect a less physiologically 
relevant extent of DNA damage.
Together, these data indicate that p21 and ATM form a posi-
tive genetic interaction that cooperates to maintain p53 protein 
activity. p21 is the most sensitive factor to oscillations under 
steady-state proliferating conditions (Fig. 11) and plays a role in 
the maintaining the p53 pulse after DNA damage since siRNA 
targeted to attenuate p21 protein abrogates the p53 pulse at 
nuclear localization and transcriptional activity of p53 protein 
and that the p53 response is quantitatively responsive to p21 gene 
dosage.
p53 protein equilibrium shift from the nuclear to cytosolic 
fractions induced by ATM inhibition. The mechanism of how 
p21 maintains nuclear p53 and primes the transcription response 
is currently undefined. Two predominating ways for wt-p53 pro-
tein to be inactivated in cancers include defects in ATM-pathway 
activation and stimulation of MDM2-mediated nuclear export, 
transrepression, and/or degradation of p53 protein. p53 protein 
is not de-stabilized by p21 gene deletion; indeed there are defects 
in MDM2-dependent p53 degradation in the absence of p21 
(Fig. 1). However, the apparent exclusion of p53 protein from 
chromatin fractions in the absence of p21 might indicate an acti-
vated MDM2 export pathway despite their being very low levels 
of MDM2. However, the treatment of p21-null cells with the 
MDM2-inhibitor Nutlin49 does not completely restore nuclear 
localization of p53 protein in p21-null cells (Fig. 10A, lanes 13–15 
vs. lane 9–11), under conditions where treatment of wt-cells with 
Nutlin resulted in enhanced p53 protein predominantly in the F3 
nuclear fraction (Fig. 10A, lane 7 vs. 3). Under these conditions, 
Nutlin reduces the levels of MDM2 in the nuclear F3 fraction 
(Fig. 10C, lane 3 vs. 7) and increases MDM2 in the F1 cytosolic 
fraction (Fig. 10C, lane 1 vs. 5). These data indicate that low 
levels of MDM2 activity per se cannot account for the redistri-
bution of p53 from chromatin to cytosolic fractions in p21-null 
cells.
If p21 is a component of an intrinsic positive feedback loop, 
then it is likely that the protein interacts with the extrinsic ATM-
dependent p53 activating system. A recent report has highlighted 
that ATM is a component of an extrinsic DNA damage recogni-
tion system that maintains waves of p53 protein stabilization and 
degradation after DNA damage.12 Further, ATM and p21 deletion 
cooperate to promote a tumor spectrum similar to p53-null ani-
mals.24 It could be predicted that the mechanism of p21-mediated 
activation of the p53 pathway therefore involves p21-dependent 
control over ATM. As such, we examined whether ATM inhibi-
tion induces the phenotype observed in p21-null cells; equilib-
rium shift involving p53 nuclear exclusion and accumulation of 
cytosolic p53 protein. The treatment of HCT116 cancer cells with 
the specific ATM inhibitor (KU55993,50) resulted in significant 
cytosolic accumulation of p53 protein (Fig. 10D, lanes 5 and 6 
vs. 1 and 2) that was similar to the redistribution of p53 protein 
observed in p21-null cells (Fig. 10D, lanes 9 and 10). As a con-
trol, the treatment of wt HCT116 cells with a specific DNA-PK 
inhibitor did not alter p53 protein nuclear localization (Fig. 10F, 
lanes 7 vs. 3). This effect of ATM-inhibition on redistribution 
Figure 9 (See opposite page). Analysis of p53-dependent gene expression alterations in p21+/+, p21+/- and p21-/- murine B cells. (A–C) murine p53-gene 
array. B cells isolated from animals with the following genotype (p21+/+, p21+/- and p21-/-) were processed for total RNA isolation. DNA microarrays were 
used to profile the expression of genes related to p53-mediated signal transduction (oligoGeArray® System, SuperArray) to indicate the extent of 
p53 activity in the indicated genetic backgrounds. Normalization of housekeeping gene expression are indicated by red arrows. the part of genes 
analyzed in detail are indicated by the red boxes and representative changes in gene expression as a function of genetic background of selected p53 
responsive genes using GeArray expression Analysis Suite software (F and G; http://www.sabiosciences.com/support_software.php) are highlighted 
in parts (H–M) and include MDM2, perp, Bax, Caspase-2, Hsp90 and Jun. (D and e) p53 protein is mislocalized in p21-/- B cells. protein from B-cells were 
extracted according to their subcellular localization: F1-Cytosol; F2-Membrane/organelle; F3-Nucleus; F4-Cytoskeleton (proteoextract® Subcellular pro-
teome extraction Kit (S-peK), Calbiochem®). proteins from each fraction were resolved by SDS-pAGe and analyzed by immunoblotting for p53 and p21.
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in the p53 feedback loop and experiments were proposed on 
methodologies to tackle these paradigms.21 The incorporation 
of a positive feedback loop to the p53 feedback pathway would 
provide a mechanism to account for lack of dosage compensa-
tion and would also suggest that the positive branch would be 
rate-limiting.
We reasoned that a positive branch integrated into the p53 
negative feedback loop could be an intrinsic factor (i.e., a gene 
induced by p53) rather than an extrinsic factor (i.e., like ATM-
DNA damage response12). As such, we first examined whether 
one of the first genes identified as a p53-inducible gene product, 
p21WAF1, might be a component of a positive feedback. p21 was 
originally identified and characterized molecularly as a novel p53-
induced gene product that could mediate a cell cycle arrest by 
virtue of blocking cyclin-dependent protein kinase function.53,54 
Although proposed originally to be a “mediator” of p53 tumor 
suppressor functions,53 this concept was not so well supported 
based on the earlier data showing that p21-null animals do not 
have the same cancer incidence as p53-null animals.46 However, 
it is now known that p21+/- animals have elevated tumor cell 
proliferation relative to p21+/+,46 and p21-null animals are more 
tumor prone though not at the younger age of p53-null ani-
mals.22 Our data demonstrate that loss or of attenuation of p21 
can stimulate nuclear export of p53, inhibition of p53 function, 
and enhanced stabilization of transcriptionally inactive p53. As 
such, p21 can fulfil the definition of a factor that can function in 
a positive feedback loop towards p53 protein that is counteracted 
by negative feedback loop factors like MDM2 (Fig. 11K). This is 
consistent with earlier discoveries that high levels of p53 protein 
caused by transcriptional inhibitors can be functionally attenu-
ated with reduced responsiveness to stresses such as DNA dam-
aging agents.55,56 These data together indicate that factors that 
mediate degradation of p21 protein would attenuate p53 function 
and perhaps stabilize the p53 protein in a non-functional state 
by virtue of reducing the MDM2-dependent negative feedback 
loop. Such factors that regulate p21 protein stability include pro-
tein kinases like atypical-PKCs and ubiquitin ligases like MDM2 
or proteasomal subunits that in turn could regulate p53 protein 
function.57-60
Other genetic studies have supported a role for p21 as a 
tumor modifier. One striking alteration of p21 knockout kera-
tinocytes is their very aggressive tumorigenic behavior after 
ras oncogene transformation.61 Although p21 is thought to be 
one of the primary mediators of p53-induced growth inhibi-
tion, its role in p53 tumor suppression has been questioned, as 
p21 knockout mice do not exhibit an increased rate of spon-
taneous tumor formation relative to p53-null mice.62 However, 
the spontaneous tumors formed in the p53 knockouts do not 
involve the epidermis, suggesting that p53 may exert different 
2.5 Gy of radiation (Fig. 11I, lanes 1–10). This latter point is 
important, as it is not p53 protein stabilization by damage that 
is necessarily defective upon transient inhibition of ATM with 
a chemical inhibitor or attenuation of p21 using siRNA, but 
it is the pulses that are compromised in the absence of ATM 
or p21. These data suggest again that p21 plays a role in main-
taining ATM activity, which is consistent with the fact that the 
ATM inhibitor induces the same p53 nuclear exclusion phe-
notype as p21-null cells (Fig. 10). Accordingly, we evaluated 
whether there were defects in ATM-phosphorylation after DNA 
damage in p21-null cells. After irradiation of wt-cell, a classic 
induction of ATM phosphorylation is observed at 1–2 hours 
post radiation (Fig. 11J, lane 2 and 3). However, in the p21-
null cells, this full activation of ATM is delayed until 6 hours 
post irradiation (Fig. 11J, lanes 10) highlighting a quantitative 
defect in ATM activation in p21-null cells. Together, these 
data suggest that p21 forms a component of an intrinsic 
positive feedback loop that interacts with the extrinsic ATM 
pathway maintaining p53 protein in a transcriptionally compe-
tent state.
Discussion
The p21 gene as a genetic modifier of p53-dependent tran-
scription. The p53 transcription program involves hundreds 
of genes whose functions are linked to many aspects of biol-
ogy including anti-viral responses, metabolic stress, aging and 
genetic instability.51 Of these many p53-induced genes, there 
are now two (MDM2 and WIP1) that are part of a negative 
feedback loop that functions to maintain low levels of p53 
activity in undamaged cells but which are now known to play a 
role in the extrinsic ATM-“p53-pulse” induced by DNA dam-
age.12 The complete number of components to the p53 nega-
tive feedback loop are currently undefined. Feedback loops are 
integral components in biochemical and genetic signaling path-
ways that maintain stability in the biological network and the 
p53-MDM2 feedback appears to operate like a digital system.19 
However, one of the striking features of the p53 response to 
DNA damage is that there is no dosage compensation in p53+/- 
heterozygote cells14,52 and p53 “knock-ins” have elevated p53 
signaling responses;15 i.e., if the MDM2-feedback loop oper-
ated with a strict dosage compensation mechanism then p53+/- 
and p53+/+/+ animals would have cells with the same p53 specific 
activity. The fact that p53 activation appears rate-limiting, 
rather than p53 inhibition, suggests that the negative feedback 
loop is not rate-limiting and that MDM2 does not drive p53 
into a steady-state equilibrium that is independent of p53-gene 
dosage. Mathematical modeling has provided novel insight into 
this problem; a positive and negative signal appears to operate 
Figure 10 (See opposite page). effects of AtM and MDM2 inhibition using small molecules on p53 subcellular localization. (A–C) Nutlin effects on 
p53 localization. the indicated cell parts (wt or p21-/-) were treated with Nutlin as indicated. (D–G) pI3K effects on p53 localization in HCt116 cell parts. 
the indicated cell parts (wt or p21-/-) were treated with the indicated inhibitors (AtM (KU55993) or DNA-pK). protein was extracted according to their 
subcellular localization: F1-Cytosol; F2-Membrane/organelle; F3-Nucleus; F4-Cytoskeleton (proteoextract® Subcellular proteome extraction Kit (S-peK), 
Calbiochem®). proteins from each fraction were resolved by SDS-pAGe and analyzed by immunoblotting for p53, MDM2, p21. (H–N) effects of AtM in-
hibitors in normal human fibroblasts. Fibroblasts were treated, as indicated with siRNA targeting p21 and MDM2 or with the kinase inhibitors specific 
for AtM or DNA-pK. 
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mouse models of cancer except in a telomerase deficient animal 
model and p53 mutant knock-in mouse models for Li-Fraumeni 
syndrome.65 The development of carcinomas in the ATM and 
tumor suppressing functions in this tissue. 
In fact, mutation and/or loss of the p53 gene 
has been shown to play an important role in 
chemically induced mouse skin carcinogen-
esis, but only in the late stages of benign to 
malignant tumor conversion.16 The possibility 
that p53 and p21 genes have at least partially 
overlapping tumor suppressing functions in 
keratinocytes is indicated by the highly aggres-
sive tumorigenic behavior of ras transformed 
p21 knockout keratinocytes, which is similar 
to that previously reported for ras-transformed 
keratinocytes with a p53 deletion.63 A recent 
study has also supported an involvement of 
the p21 gene in p53-mediated tumor suppres-
sion.47 In a p21+/+ and p21-null background, 
p53-dependent pathways (apoptosis, cell cycle 
block and cancer incidence) were quantified by 
examining tumor susceptibility in mice carry-
ing two or three copies of the p53 gene. The 
loss of p21 reduced the normally enhanced 
p53-mediated cell cycle arrest in the triploid-
p53 background and also reduced the cancer 
suppressor function of the super-p53 mice in 
fibrosarcomas. These data suggest that the 
p53-dependent cell cycle arrest driven through 
the p21 gene plays an important role in medi-
ating p53-dependent cancer protection and 
is consistent with the positive role for p21 in 
maintaining the transcription program in our 
current studies. However, the HCT116 p21-
null cells remain sensitive to damage induced 
apoptosis (Fig. 3) and the p53-apoptotic pro-
gram is maintained in the p21-null super-p53 
mice47 suggesting that the p53-p21 positive 
feedback loop might confined genetically to 
the growth arrest or possible transcription-
dependent senescence pathway. Alternatively, 
the p53 protein that accumulates cytosolically 
in p21-null cells might function as a pro-apop-
totic signal via mitochondrial-dependent and 
p53 transcriptional-independent pro-apoptotic 
pathways.64
The observations in this report that ATM 
inhibition or p21 attenuation promotes p53 
cytosolic accumulation suggest a positive 
genetic interaction between the two proteins 
in maintaining a transcriptionally active p53 
protein. This is consistent with the pheno-
types observed in the ATM and p21 double-
null mice. The tumor spectrum observed in 
these latter animals mice can be divided into 
two groups. The first group are those whose 
early tumor spectrum was lymphomas and sarcomas, which was 
similar to that observed in p53-null mice.24 The second group 
are those whose late-onset cancers are not frequently observed in 
Figure 11. the role of p21 in regulating X-ray induced p53 protein oscillation. (A) p21 oscilla-
tions in cycling cells. HCt116 cells were plated at very low density and cells were harvested 
every half hour for the indicated time course for immunoblotting p21, MDM2 and actin. 
(B–H) Analysis of the dynamic changes p53-p21-MDM2 levels after irradiation. MCF7 cells 
were left untreated (lanes 1–9) or irradiated with 2.5 Gy or 5 Gy of ionizing radiation (lanes 
10–26). Lysates were immunoblotted to detect p53, p21 and MDM2 protein levels. (o/e) 
indicates and over-exposure of the chemiluminescent detection to observe low levels of 
the indicated proteins. (I) effects of p21 siRNA on the p53 pulse. MCF7 cells were irradiated 
after p21 depletion using siRNA and the effects of radiation on the p53 pulse was evaluated 
by immunoblotting for MDM2 and p53. (J) Defects in AtM activation in p21-/- cells. the indi-
cated cell parts were exposed to ionizing radiation and immunoblotted for phospho-AtM at 
the indicated times points post-damage. (K) Model highlighting the relationship between 
two p53-inducible gene products-MDM2 and p21-one of which is a negative regulator and 
catalyzes p53 degradation by the proteasome and the other is an intrinsic positive effector 
and maintains nuclear localization of p53 plus the extrinsic AtM DNA damage pulse.
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p21 double-null mice is of particular interest in its epistatic corre-
lation with TERT and p53 double null mice since ATM activates 
p53 in response to DNA damage and is also involved in telomere 
maintenance. Our current studies involve understanding further 
how compartmentalization of the “intrinsic” (i.e., p53-depe-
nent genes) p53 pathway composed of positive effectors like p21 
or negative effectors like MDM2-WIP1 function to regulate the 
intrinsic p21 oscillation and the extrinsic ATM-p53-pulse that is 
activated by DNA-damage.12
Materials and Methods
Experimental reagents. Primary antibodies against β-actin, 
GADD34, HSP70, PML, 14-3-3σ and Cyclin E were purchased 
from Abcam (Cambridge, UK). Anti-IRF-1 antibody was pur-
chased from BD Biosciences (Oxford, UK). Primary antibod-
ies against MDM2 (4B2), and p53 (DO1) were obtained from 
Moravian Biotechnology (Brno, Czech Republic). Anti-p21 
(Ab1) antibody was purchased from Calbiochem (Nottingham, 
UK). Primary antibodies against Bax (N-20), CHK1 (G-4) and 
CHK2 (A-12) were purchased from Santa Cruz (CA USA).
Cell culture and isolation of mouse B-cells. The HCT116 
p21-/-, p53-/- and Bax-/- isogenic derivatives of the wild-type 
HCT116 (HCT116 WT) colorectal cancer cell line, generated 
by targeted homologous recombination, were a generous gift 
from B. Vogelstein (John Hopkins Oncology Center, Baltimore, 
MD). Cells were maintained in McCoy’s 5A medium. Normal 
human Fibroblast (NHF) cells were obtained from Promocell 
(Heidelberg, Germany) and maintained in HepesBSS medium. 
MCF-7 cells were maintained in Dulbecco’s modified Eagles 
medium. All media was supplemented with 10% fetal bovine 
serum (Invitrogen Inc., Carlsbad, CA) and cells were maintained 
at 37°C in a humidified 5% CO
2
 incubator. p21 homozygous 
(Cdkn1a-/-) heterozygous (Cdkn1a+/-) and wild type (Cdkn1a+/+) 
mice were supplied by the Roslin Institute, Midlothian UK. 
The homozygous mice mating system was purchased from 
The Jackson Laboratory (Maine), JAX® Mice strain name: B6; 
129S2-Cdkn1atm1Tyj/J. The isolation of B cells from mice spleens 
was achieved using the QuadroMACSTM separation system 
(Miltenyi Biotec, Bergisch Gladbach, Germany). Spleens were 
removed from mice and stored at 4°C in IMDM media supple-
mented with 5% Fetal bovine serum and 50 μM 2-mercapto-
ethanol. Each spleen was macerated with a fine syringe needle 
and cells were flushed out. Generally, ~1 x 108 cells per spleen 
were obtained. Cells were centrifuged at 300 g for 10 min at 
4°C. The cell pellet was resuspended in 900 μl separation 
buffer (2 mM EDTA, 0.5% BSA in PBS pH 7.2) and 100 μl 
CD45R mouse MACS® Microbeads (Miltenyi Biotec, Bergisch 
Gladbach, Germany), and incubated for 15 min at 4°C. Cells 
were washed with 10 ml separation buffer and resuspended 
in 500 μl separation buffer. A MACS® LS separation column 
(Miltenyi Biotec, Bergisch Gladbach, Germany) was placed in 
the QuadroMACSTM separation unit (Miltenyi Biotec, Bergisch 
Gladbach, Germany) and washed with 3 ml separation buffer. 
The cell suspension was applied to the column and the column 
was washed three times with 3 ml separation buffer. The column 
was then removed from the magnetic field and B-cells were 
flushed out with 5 ml separation buffer into a clean falcon tube. 
Cells were collected by centrifugation at 200 g for 5 min at room 
temperature, resuspended in culture media and seeded at a cell 
density of 0.5 x 106 cells/ml.
Transient transfection, stable transfection and siRNA 
interference. Transient and stable transfections were car-
ried out using the lipofectamineTM 2000 transfection reagent 
(Invitrogen Inc., Carlsbad, CA) based on the manufacturer’s rec-
ommendations. The quantity of DNA transfected is indicated in 
each experiment. In the construction of the p21 stable cell lines, 
HCT116 p21-/- cells were transfected with pIRESpuro2 vector 
(Clontech, CA) expressing full length p21 and puromycin-N-
acetyl-transferase. After 24 hr incubation at 37°C, cells contain-
ing the plasmid were selected for by the addition of puromycin 
(Calbiochem, Nottingham, UK). Fresh medium containing 5 μg/
ml puromycin was added after a majority of cells died. Individual 
colonies were selected and expanded under selection conditions. 
Small interfering RNA (siRNA) mediated gene knock-down 
was achieved by transfecting siRNAs (Dharmacon Inc., IL) into 
cells using LipofectamineTM 2000 (Invitrogen Inc., Carlsbad, 
CA) in accordance with the manufacturer’s recommendations. 
p21 siRNA, MDM2 siRNA and control siRNA (SMARTpoolTM 
Dharmacon Inc., IL) were used at a final concentration of 33 nM. 
After transfection cells were incubated at 37°C in 5% CO
2
 for 
24–48 hr, harvested and analyzed by immunoblotting.
Genotoxic or drug treatments of cells. Cells were grown to 
70% confluency before treating with indicated drug or stress. 
Cells were irradiated in culture medium using a Faxitron® 
cabinet X-ray system, 43855D (Faxitron X-ray Corporation, 
Lincolnshire, IL USA), at a central dose rate of 2 Gy/min. Cells 
were irradiated at the stated doses and harvested at the stated time 
points. Cells were treated with various small molecule inhibitors 
including Nutlin-3 (Sigma, Dorset, UK), KU55933 and NU7441 
(a kind gift from KuDOS Pharmaceuticals, Cambridge, UK). 
Cyclohexamide was dissolved in DMSO at a stock concentration 
of 100 mg/ml and added directly into the culture media at a final 
concentration of 30 μg/ml. Cells were harvested at 0 hr, 0.5 hr, 
1 hr, 2 hr, 4 hr after treatment and analyzed by immunoblot-
ting. Polyinosinic polycytidylic acid [poly(I).poly(C)] (Sigma) 
was dissolved in 0.5 M Hepes pH 7.5 at a stock concentration of 
25 mg/ml. The stated concentration was added to cells in culture 
medium, and cells were harvested at the stated time points.
Protein detection. Cells were lysed in urea lysis buffer (7 M 
urea, 0.1 M DTT, 0.05% Triton X-100, 25 mM NaCl, 20 mM 
Hepes pH 7.5). Equal amounts of protein were separated by SDS 
polyacrylamide gel electrophoresis (SDS PAGE), transferred to 
Hybond-C nitrocellulose membrane (Amersham Pharmacia 
Biotech, Buckinghamshire, UK) and hybridized to an appro-
priate primary antibody and HRP-conjugated secondary anti-
body for subsequent detection by ECL. Following SDS-PAGE, 
resolved proteins were Coommassie stained. Protein staining 
of polyacrylamide gels was achieved by a 30 min incubation 
with Coommassie blue solution (45% Methanol, 10% Acetic 
acid, 0.1% w/v Coomassie Blue R250). Gels were destained by 
incubating with destain (5% (v/v) Methanol, 7% (v/v) Acetic 
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stated. All fractions were stored at -70°C and analyzed by 
immunoblotting.
Chromatin protein preparation: Cell fractionation and 
nuclease digestion. Cells were fractionated by the method of 
Gilbert and Allan.42 5 x 106 cells were seeded in 15 cm diameter 
culture dishes and grown until 80% confluent. Cells were tryp-
sinized and the cell pellet resuspended in 5 ml NBA (85 mM KCl, 
5.5% (w/v) sucrose, 10 mM Tris-HCl pH 7.5, 0.2 mM EDTA, 
0.5 mM spermidine, 250 μM PMSF). An equal amount of NBB 
(85 mM KCl, 5.5% (w/v) sucrose, 10 mM Tris-HCl pH 7.5, 0.2 
mM EDTA, 0.5 mM spermidine, 250 μM PMSF, 0.1% (v/v) 
NP40) was added and the cells were incubated on ice for 3 min. 
A sample was taken of total cellular extract, mixed with an equal 
volume of SDS sample buffer and stored at -20°C. The nuclei 
were pelleted by centrifugation at 360 g for 4 min at 4°C. Nuclei 
were resuspended in NBR (85 mM KCl, 5.5% (w/v) sucrose, 10 
mM Tris-HCl pH 7.5, 1.5 mM CaCl
2
, 3 mM MgCl
2
, 250 μM 
PMSF) and digested with 8–14 units of micrococcal nuclease 
(Worthington) per 20 A
260
 units of nuclei for 10 min on ice in 
the presence of 100 μg/ml RNaseA. The reaction was stopped by 
adding 10 mM EDTA. The nuclei were washed, resuspended in 
TEEP
20
 (10 mM Tris-HCl pH 8.0, 1 mM EDTA, 1 mM EGTA, 
250 μM PMSF, 20 mM NaCl) and incubated at 4°C overnight. 
Nuclear debris was removed leaving soluble chromatin in the 
supernatant by centrifugation at 12,000 g for 5 min at 4°C. A 
sample of both the insoluble nuclear fraction and the soluble 
chromatin containing fraction was removed, mixed with an equal 
amount of SDS sample buffer and stored at -20°C. All fractions 
were resolved by SDS-PAGE and analyzed by immunoblotting.
DNA microarray. The Oligo GEArray® p53 Signaling 
Pathway Microarray for human and mouse was used to profile the 
expression of 113 genes related to p53 mediated signal transduc-
tion (SuperArray, SABiosciences, Fredrick, MD). The system was 
used according to the manufacturer’s instructions. Total RNA 
was isolated from cells using the RNeasy kit (Qiagen) according 
to the manufacturer’s instructions. TrueLabeling-AMPTM 2.0 
(SuperArray) is designed to amplify and label antisense RNA for 
hybridization to Oligo GEArray® and was used according to the 
manufacturer’s instructions. cDNA was synthesized from total 
RNA, and used as the template for cRNA synthesis in the pres-
ence of biotinylated-UTP, leading to the incorporating biotin 
labelled uridine into the newly synthesized cRNA. The cRNA 
was purified using the SuperArray ArrayGradeTM cRNA cleanup 
kit, according to the manufacturer’s instructions. The cRNA was 
hybridized to the array following the Oligo GEArray® HybTube 
Protocol. The array membrane was pre-wet with deionized water. 
GEAhyb Hybridization Solution (SuperArray) was warmed to 
60°C, added to the membrane and incubated for 2 hr at 60°C 
in a hybridization oven with slow agitation. 3 μg biotin labelled 
cRNA target was mixed with GEAhyb Hybridization Solution, 
added to the membrane, and allowed to hybridize overnight at 
60°C with slow rotation. The membrane was repeatedly washed, 
then cooled to room temperature. To prevent non-specific bind-
ing, the membrane was blocked with GEAblocking Solution Q 
(SuperArray) for 40 min with continuous rotation at room tem-
perature. The blocking solution was discarded and membrane 
acid) until bands became visible and background staining was 
removed.
p53 gene reporter assay. Cells were seeded into 6-well plates, 
and incubated until ~70% confluency was obtained before 
being transfected with 1 μg pGL3p21-Luc and 1 μg pCMVβ-
Gal DNA. Cells were incubated for 24 hr at 37°C. Cells were 
then treated and lysed at stated time points. To lyse, cells were 
washed twice in ice-cold PBS and lysed in 70 μl 5x Reporter 
Lysis Buffer (Promega, Madison, WI) on ice for 10 min. The 
cells were scraped and spun at 15,000 g for 2 min at 4°C. The 
supernatant was transferred to a fresh microcentrifuge tube and 
snap frozen in liquid nitrogen. For the Luciferase assay, the lysates 
(20 μl) were aliquoted into a white Microlite2TM 96-well ELISA 
plate (CoStar; Corning Inc., CA) on ice. 50 μl of Luciferase 
SubstrateTM from the Luciferase Assay SystemsTM (Promega, 
Madison, WI) kit was added to each well of the Microlite2 plate, 
and allowed to reach room temperature. Luciferase activity was 
quantified using a luminometer (Fluroskan Ascent FL, Thermo 
Fisher Scientific, MA). For the β-Galactosidase assay, the lysates 
(20 μl) were aliquoted into a clear 96-well plate at room tem-
perature, and 20 μl of β-Galactosidase 2x assay buffer (Promega, 
Madison, WI) was added and incubated for 20 min at 37°C. 
β-Galactosidase activity was quantified using a PowerwaveXSTM 
Microplate Spectrophotometer (Bio-Tek, VT) at a wavelength of 
405 nm. The results were normalized to account for variation in 
transfection efficiency, by dividing the Luciferase readout by the 
β-galactosidase readout to give relative light units.
Proteasome activity assay. Active proteasomes were obtained 
from cells as described in reference 66. Harvested cells were 
lysed with proteasome lysis buffer (20 mM Tris-HCl pH 7.2, 
0.1 mM EDTA, 1 mM 2-mercaptoethanol, 5 mM ATP, 20% 
glycerol and 0.04% NP40) by repeated pipetting, followed by 
a 20 min incubation on ice. Cell lysates were centrifuged at 
16,000 g at 4°C for 10 min. Proteasome activity was analyzed 
using a 20S Proteasome Assay Kit (Calbiochem®, Darmstadt, 
Germany) in accordance with the manufacturer’s recommenda-
tions. The 20S activity is measured by monitoring the release 
of free AMC (7-amino 4-methylcoumarin) from the fluoro-
genic proteasome specific peptide Suc-Leu-Leu-Val-Tyr-AMC. 
The rate of AMC release is measured by fluorescence spectros-
copy. Cell lysates (final concentration 0.02 mg/ml) were diluted 
in 190 μl SDS activated Reaction Buffer, added to a white 
Microlite2TM 96-well ELISA plate (CoStar; Corning Inc., CA) 
and equilibrated to 37°C. The reaction was initiated by add-
ing 10 μl of the fluorogenic peptide solution to each well. The 
intensity of fluorescence of each reaction was measured over time 
by fluorescence spectroscopy (excitation max: ~380 nm; emis-
sion max: ~460 nm) using an Envision fluorescence detector 
(Perkin Elmer, MA).
Subcellular proteome extraction. The ProteoExtract® 
Subcellular Proteome Extraction Kit (Calbiochem®, Darmstadt, 
Germany), here after referred to as S-PEK, was used to extract 
proteins from mammalian cells according to their subcellular 
localization. The kit was used in accordance with the manu-
facturer’s recommendations. All extraction buffers contain 
protease inhibitors and all steps were carried out at 4°C unless 
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convert the fluorescent intensity of the probe into values repre-
senting gene expression, and allow data analysis and quantitation 
of the microarray results.
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was incubated with alkaline phosphatase-conjugated streptavi-
din. The membrane was repeatedly washed, before being incu-
bated with CDP-Star chemiluminescent substrate (SuperArray). 
Excess CDP-Star solution was removed from the membrane and 
array image was acquired by exposure to X-ray film (Kodak, NY). 
The resulting images were scanned and saved as 16 bit TIFF files. 
The images were uploaded into the GEArray Expression Analysis 
Suite program (geasuite.superarray.com) which was used to 
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